BioNTech SE

BNTX

US09075V1026

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:23:36 2024-04-25 am EDT			5-day change	1st Jan Change
86.38 ^USD	-1.94%		+0.38%	-18.04%

03:18pm	GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology	RE
12:11pm	Scholz promises support for pharma sector in Germany as Merck invests	RE

BIONTECH : Goldman Sachs sticks Neutral

June 05, 2023 at 03:24 am EDT

In a research note published by Chris Shibutani, Goldman Sachs gives a Neutral rating to the stock. The target price is still set at USD 140.

Latest news about BioNTech SE

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology	09:18am	RE
Scholz promises support for pharma sector in Germany as Merck invests	06:11am	RE
BIONTECH : Gets a Neutral rating from Deutsche Bank	Apr. 23	ZD
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla...	Apr. 15
Market outlook is uncertain, but optimism prevails	Apr. 15
BioNTech SE Announces Three-Year Follow-Up Data from Phase 1 Trial with the mRNA-Based Individualized Neoantigen-Specific Immunotherapy Candidate Autogene Cevumeran	Apr. 08	CI
BioNTech Reports Positive 3-Year Data From Phase 1 Trial of Cevumeran in Pancreatic Cancer	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
UBS Cuts BioNTech Price Target to $101 From $110, Maintains Neutral Rating	Mar. 27	MT
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET	Mar. 26	DJ
European Midday Briefing : Investors Hold Back Ahead of Key Inflation Print	Mar. 26	DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	Mar. 26	DJ
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET	Mar. 26	DJ
BioNTech gets US agency notice over default on COVID vaccine royalties	Mar. 25	RE
Moderna, Inc. prepares for the post-Covid era	Mar. 25
BioNTech gets notice from US agency over default on COVID vaccine royalties	Mar. 25	RE
BioNTech gets notice from NIH on default on royalties	Mar. 25	RE
BioNTech SE Receives Notice of Default from the NIH	Mar. 25	CI
BIONTECH : Deutsche Bank remains Neutral	Mar. 22	ZD
TD Cowen Adjusts BioNTech Price Target to $95 From $101, Maintains Market Perform Rating	Mar. 21	MT
BIONTECH : A miss is a miss	Mar. 21
BIONTECH : Deutsche Bank reaffirms its Neutral rating	Mar. 21	ZD
BIONTECH : Goldman Sachs reiterates its Neutral rating	Mar. 21	ZD
Wall St ends higher as Fed sees three rate cuts	Mar. 20	RE
BIONTECH : Jefferies sticks Neutral	Mar. 20	ZD

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BIONTECH : A miss is a miss

March 21, 2024 at 09:27 am EDT

More Strategies

Ratings for BioNTech SE

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

82.43 EUR

Average target price

106.6 EUR

Spread / Average Target

+29.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIONTECH SE	-18.04%	21.23B
VERTEX PHARMACEUTICALS INCORPORATED	-2.62%	104B
REGENERON PHARMACEUTICALS, INC.	+1.16%	97.42B
ARGENX SE	+0.90%	22.2B
GENMAB A/S	-10.65%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-17.78%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.40%	13.98B
SAREPTA THERAPEUTICS, INC.	+27.72%	11.66B
LEGEND BIOTECH CORPORATION	-25.58%	8.22B

Bio Therapeutic Drugs

BioNTech SE

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

BIONTECH : Goldman Sachs sticks Neutral

Latest news about BioNTech SE

Chart BioNTech SE

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for BioNTech SE

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs